The specific role of luminal carbonic anhydrase in bicarbonate reabsorption by the proximal tubule has not been established because it has been difficult to inhibit selectively the luminal enzyme without simultaneous inhibition of the cytoplasmic enzyme. The present experiments employed in vivo microperfusion, microcalorimetry, and microelectrode techniques to determine the effects of luminal application of a dextran-bound carbonic anhydrase inhibitor (DBI) on bicarbonate reabsorptive rate (JtCO2) and intraluminal pH in the rat proximal convoluted tubule. Tubules were perfused at 20 nl/min with an artificial ultrafiltrate. Aminoethyl dextran (AED) with no enzyme-inhibitor activity was added to the control perfusate, and the effects of the parent inhibitor STZ not bound to dextran were also determined. Both DBI and STZ significantly reduced JtCO2 from 138 +/- 10 pmol X mm-1 X min-1 (control) to 30 +/- 4 and 30 +/- 9, respectively. In contrast to the indistinguishable effects on JtCO2, intraluminal pH measured close to the site of perfusion was 6.80 +/- 0.02 during DBI perfusion, whereas with STZ perfusion the pH was 7.24 +/- 0.04 (P less than 0.001). Using the collected perfusate total CO2 concentration and a renal cortical PCO2 of 60 mmHg, the calculated equilibrium pH for this solution was 7.27. DBI inhibited only luminal carbonic anhydrase, therefore. We conclude that luminal carbonic anhydrase is in functional contact with proximal tubule fluid and is necessary for at least 80% of bicarbonate reabsorption by this segment.(ABSTRACT TRUNCATED AT 250 WORDS)

Monkeys that receive chronic low dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration develop deficits in spatial delayed-response task performance. The present study examined the extent to which SIB-1553A [(Ϯ)-4-{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride], a novel neuronal nicotinic acetylcholine receptor (nAChR) agonist with selectivity for ␤4 subunit-containing nAChRs, could counteract this cognitive deficit produced by CLD MPTP exposure. Prior to MPTP treatment, monkeys displayed a delay-dependent decrement in performance on a variable delayed response task. CLD MPTP treatment caused a shift to a delay-independent pattern of responding on this task, such that short-delay trials were performed as poorly as long-delay trials. At lower doses (e.g., 0.025 mg/kg), SIB-1553A significantly improved performance on short-delay trials but only at 24 h after drug administration. At higher doses (e.g., 0.50 mg/kg), SIB-1553A significantly improved performance on both short-and longdelay trials at both 20 min and 24 h after drug administration. When tested 24 h after drug administration, monkeys performed long-delay trials with greater accuracy than they did under normal (pre-MPTP) conditions. These results suggest that at lower doses, SIB-1553A may be more effective in improving attentional deficits associated with CLD MPTP exposure, whereas at higher doses, SIB-1553A may effectively improve both attentional and memory performance.

No abstract

No abstract

GM1 ganglioside administration has previously been shown to increase striatal dopamine levels and to enhance the density of tyrosine hydroxylase-positive fibers in the striatum of monkeys made parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The present study examined the extent to which GM1 administration promotes recovery of dopamine terminals and reverses lesion-induced changes in postsynaptic receptors in the striatum of MPTP-treated monkeys. All MPTP-treated animals developed severe parkinsonism. GM1-treated monkeys exhibited significant functional recovery after 6 weeks of treatment, whereas saline-treated controls remained parkinsonian over the same time period. MPTP exposure resulted in profound decreases in [(3)H]-mazindol binding to dopamine transporters in the caudate and putamen and increased D1 and D2 receptor binding in several striatal regions. GM1 treatment resulted in significant increases in striatal [(3)H]-mazindol binding and decreases in D1 binding compared to control animals in many striatal regions. GM1 treatment did not significantly affect D2 binding. These results show that GM1 treatment can partially restore striatal dopaminergic terminals and partially reverse postsynaptic changes in dopamine receptors in a nonhuman primate model of parkinsonism.